February 23, 2017

European Commission Approves ALK Inhibitor Alecensa for Some Lung Cancer Patients

News

The European Commission has conditionally authorized F. Hoffmann-La Roche to market the ALK inhibitor Alecensa (alectinib hydrochloride) for treatment of patients with ALK-positive, metastatic non-small cell lung cancer (NSCLC) who are intolerant ... Read more

October 18, 2016

Zykadia Better than Chemo as Second-line Treatment of Specific Lung Cancer, Trial Finds

News

Patients with non-small cell lung cancer (NSCLC) who have an ALK gene rearrangement and who were previously treated with the ALK inhibitor Xalkori (crizotinib) may strongly benefit from treatment with another ... Read more